4θrbo A,Arnes M,Hancke C,et al.Treatment results of endometrial hyperplasia after prospective D-score classification:a follow-up study comparing effect of LNG-IUD and oral progestins versus observation only[J].Gynecol Oncol,2008,111(1):68-73.
5Horn LC,Schnurrhusch U,Bilek K,et al.Risk of progression in complex and atypical endometrial hyperplasia:clinicopathologic analysis in cases with and without progestogen treatment[J].Int J Gynecol Cancer,2004,14(2):348-353.
6Vereide AB,Kaino T,Sager G,et al.Bcl-2,BAX,and apoptosis in endometrial hyperplasia after high dose gestagen therapy:a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogeaterone[J].Gynecol Oncol,2005,97(3):740-750.
7Vereide AB,Kaino T,Sager G,et al.Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors(PRA and PRB),and estrogen receptors(ERalpha and ER-beta)in human endometrial hyperplasia[J].Gynecol Oncol,2006,101(2):214-223.
8Buttini MJ,Jordan SJ,Webb PM.The effect of the levonorgestrel releasing intrauterine system on endomatrial hyperplasia:an Australian study and systematic review[J].Aust N Z J Obstet Gynaecol,2009,49(3):316-322.
9Wildemeersch D,Janssens D,Pylyser K,et al.Management of patients with non-atypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system:long-term follow-up[J].Maturitas,2007,57(2):210-213.
10Chen X,Zhang Z,Feng Y,et al.Aberrant survivin expression in endometrial hyperplasia:another mechanism of progestin resistance[J].Mod Pathol,2009,22(5):699-708.
